JP2016523285A5 - - Google Patents

Download PDF

Info

Publication number
JP2016523285A5
JP2016523285A5 JP2016522933A JP2016522933A JP2016523285A5 JP 2016523285 A5 JP2016523285 A5 JP 2016523285A5 JP 2016522933 A JP2016522933 A JP 2016522933A JP 2016522933 A JP2016522933 A JP 2016522933A JP 2016523285 A5 JP2016523285 A5 JP 2016523285A5
Authority
JP
Japan
Prior art keywords
composition
composition according
msc
administered
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016522933A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016523285A (ja
JP6412933B2 (ja
Filing date
Publication date
Priority claimed from GB201311290A external-priority patent/GB201311290D0/en
Priority claimed from GB201319004A external-priority patent/GB201319004D0/en
Application filed filed Critical
Priority claimed from PCT/IB2014/062598 external-priority patent/WO2014207679A1/en
Publication of JP2016523285A publication Critical patent/JP2016523285A/ja
Publication of JP2016523285A5 publication Critical patent/JP2016523285A5/ja
Application granted granted Critical
Publication of JP6412933B2 publication Critical patent/JP6412933B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016522933A 2013-06-25 2014-06-25 免疫調節活性を有する細胞集団、その調製方法および使用 Active JP6412933B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB201311290A GB201311290D0 (en) 2013-06-25 2013-06-25 Medical use
GB1311290.9 2013-06-25
GB1319004.6 2013-10-28
GB201319004A GB201319004D0 (en) 2013-10-28 2013-10-28 Medical use
PCT/IB2014/062598 WO2014207679A1 (en) 2013-06-25 2014-06-25 Cell populations having immunoregulatory activity, methods for the preparation and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018186262A Division JP6764912B2 (ja) 2013-06-25 2018-10-01 免疫調節活性を有する細胞集団、その調製方法および使用

Publications (3)

Publication Number Publication Date
JP2016523285A JP2016523285A (ja) 2016-08-08
JP2016523285A5 true JP2016523285A5 (enExample) 2017-08-03
JP6412933B2 JP6412933B2 (ja) 2018-10-24

Family

ID=51257544

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016522933A Active JP6412933B2 (ja) 2013-06-25 2014-06-25 免疫調節活性を有する細胞集団、その調製方法および使用
JP2018186262A Active JP6764912B2 (ja) 2013-06-25 2018-10-01 免疫調節活性を有する細胞集団、その調製方法および使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018186262A Active JP6764912B2 (ja) 2013-06-25 2018-10-01 免疫調節活性を有する細胞集団、その調製方法および使用

Country Status (4)

Country Link
US (1) US20160120910A1 (enExample)
EP (1) EP3013943B1 (enExample)
JP (2) JP6412933B2 (enExample)
WO (1) WO2014207679A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060045872A1 (en) 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
MX342474B (es) 2005-09-23 2016-09-30 Cellerix Sl Poblaciones celulares con actividad inmunoreguladora, método de aislamiento y usos.
EP3160480B1 (en) * 2014-06-30 2020-09-09 TiGenix, S.A.U. Mesenchymal stromal cells for treating rheumatoid arthritis
WO2016170187A2 (en) * 2015-04-24 2016-10-27 Tigenix, S.A.U Biomarkers for determining the clinical response to cell therapy
CN105062967A (zh) * 2015-09-01 2015-11-18 沈慧勇 一种人骨髓间充质干细胞的制备方法及其应用
GB201604304D0 (en) 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
IT201700043316A1 (it) * 2017-04-20 2018-10-20 Lipogems Int S P A Drug delivery system
MX2021010221A (es) * 2019-02-27 2021-09-21 Takeda Pharmaceuticals Co Poblaciones mejoradas de celulas germinales para terapia alogenica.
KR20210149148A (ko) * 2019-05-21 2021-12-08 이엠오 바이오메디슨 코퍼레이션 면역-관련 질환 치료에서의 중간엽 줄기 세포의 용도
CN114395609A (zh) * 2022-02-09 2022-04-26 湖南源品细胞生物科技有限公司 一种具有高免疫调节潜力的人间充质干细胞的筛选方法
US20240082365A1 (en) * 2022-09-10 2024-03-14 James Veltmeyer Multidisciplinary treatment of chronic disease using regenerative cells and technologies
EP4623302A1 (en) 2022-11-23 2025-10-01 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Biomarkers predictive of immunomodulatory mesenchymal stromal cells

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU673877B2 (en) 1992-12-02 1996-11-28 Shell Internationale Research Maatschappij B.V. Azoxycyanobenzene derivatives
US5578475A (en) 1993-07-12 1996-11-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
US6051429A (en) 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
ATE285477T1 (de) 1995-06-07 2005-01-15 Inex Pharmaceutical Corp Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
US5705308A (en) 1996-09-30 1998-01-06 Eastman Kodak Company Infrared-sensitive, negative-working diazonaphthoquinone imaging composition and element
US20080095749A1 (en) * 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
MX342474B (es) * 2005-09-23 2016-09-30 Cellerix Sl Poblaciones celulares con actividad inmunoreguladora, método de aislamiento y usos.
KR20100076031A (ko) * 2007-10-17 2010-07-05 티엑셀 Ｔｒ１ 세포, 중간엽 줄기 세포 및 이들의 용도
WO2011047345A2 (en) * 2009-10-15 2011-04-21 Tai June Yoo Methods of treating diseases of conditions using mesenchymal stem cells
WO2012095743A2 (en) * 2011-01-12 2012-07-19 Cellerix Sa Methods and compositions for use in intralymphatic cellular therapies
WO2012123401A1 (en) * 2011-03-11 2012-09-20 Tigenix, S.A. Cell populations having immunoregulatory activity, method for isolation and uses

Similar Documents

Publication Publication Date Title
JP2016523285A5 (enExample)
Mamidi et al. Comparative cellular and molecular analyses of pooled bone marrow multipotent mesenchymal stromal cells during continuous passaging and after successive cryopreservation
Ejtehadifar et al. The effect of hypoxia on mesenchymal stem cell biology
Galderisi et al. The gap between the physiological and therapeutic roles of mesenchymal stem cells
Li et al. Bone‐marrow‐derived mesenchymal stem cells for organ repair
Kariminekoo et al. Implications of mesenchymal stem cells in regenerative medicine
Van Laar et al. Adult stem cells in the treatment of autoimmune diseases
Capelli et al. Minimally manipulated whole human umbilical cord is a rich source of clinical-grade human mesenchymal stromal cells expanded in human platelet lysate
Parekkadan et al. Mesenchymal stem cells as therapeutics
Coulson-Thomas et al. Extrinsic and intrinsic mechanisms by which mesenchymal stem cells suppress the immune system
JP2017520583A5 (enExample)
Rastegar et al. Mesenchymal stem cells: Molecular characteristics and clinical applications
Gang et al. In vitro mesengenic potential of human umbilical cord blood-derived mesenchymal stem cells
JP2016116523A5 (enExample)
JP2014208682A5 (enExample)
JP2015507921A5 (enExample)
EP3534921A1 (en) Mesenchymal stem cells populations, their products, and use thereof
RU2016151738A (ru) Мезенхимальные стромальные клетки для лечения синдрома системной воспалительной реакции
JP2014509319A5 (enExample)
MX2017004691A (es) Bloqueo de cd73.
JP2009508507A5 (enExample)
MX338931B (es) Composiciones y metodo para tratar gliobastoma (gbm).
EA201790025A1 (ru) Создание банка мезенхимальных стромальных клеток из объединенных мононуклеарных клеток нескольких доноров костного мозга
EP4527460A3 (en) Immunoprivileged bioactive renal cells for the treatment of kidney disease
Nemeth et al. Bone marrow stromal cells as immunomodulators. A primer for dermatologists